The EU Falsified Medicines Directive (FMD) deadline is now days away and all segments of the pharmaceutical supply chain are focused on finalising their solutions to comply with the regulation. It is vital that companies are also prepared for three important exception-based use cases that, if unaccounted for, will mean non-compliance with the FMD. Larry Hall at TraceLink describes each use case and the solution required.